{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=19",
    "query": {
      "intervention": "Formulation #2",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 1742,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T01:35:12.172Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01149720",
      "title": "Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Tivantinib (ARQ 197) Capsule",
          "type": "DRUG"
        },
        {
          "name": "Tivantinib (ARQ 197) Tablet",
          "type": "DRUG"
        },
        {
          "name": "Tivantinib (ARQ 197) Capsule D, oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2010-07",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 4,
      "location_summary": "Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01149720"
    },
    {
      "nct_id": "NCT07646613",
      "title": "Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "ASY202",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Aspeya, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-05-19",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Lemon Grove, California • Walnut Creek, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07646613"
    },
    {
      "nct_id": "NCT00934674",
      "title": "Study Comparing Two Different Tablet Formulations Of Bosutinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "SKI-606 (Bosutinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-07",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2009-09-02",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00934674"
    },
    {
      "nct_id": "NCT04190628",
      "title": "Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "BRAF V600 Mutation"
      ],
      "interventions": [
        {
          "name": "ABM-1310",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ABM Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2020-06-16",
      "completion_date": "2024-04-05",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Stanford, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04190628"
    },
    {
      "nct_id": "NCT06626633",
      "title": "2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CRD3874",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2024-08-26",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06626633"
    },
    {
      "nct_id": "NCT04771390",
      "title": "Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors Harboring NTRK Fusion"
      ],
      "interventions": [
        {
          "name": "Selitrectinib (BAY2731954) Adult tablet",
          "type": "DRUG"
        },
        {
          "name": "Selitrectinib (BAY2731954) Pediatric tablet",
          "type": "DRUG"
        },
        {
          "name": "Selitrectinib (BAY2731954) Oral solution",
          "type": "DRUG"
        },
        {
          "name": "Selitrectinib (BAY2731954) Oral suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2021-02-16",
      "completion_date": "2021-07-06",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771390"
    },
    {
      "nct_id": "NCT01377662",
      "title": "PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Methamphetamine Dependence",
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "OND-PR002 and MPh-IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tong Lee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-08",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2014-10-07",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01377662"
    },
    {
      "nct_id": "NCT00858468",
      "title": "Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza virus vaccine (2004-2005 Formulation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "9 Months",
        "sex": "ALL",
        "summary": "2 Months to 9 Months"
      },
      "enrollment_count": 394,
      "start_date": "2005-04",
      "completion_date": "2006-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858468"
    },
    {
      "nct_id": "NCT00736190",
      "title": "A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2008-08",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 21,
      "location_summary": "Fountain Valley, California • Hacienda Heights, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Hacienda Heights",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey Park",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00736190"
    },
    {
      "nct_id": "NCT01942668",
      "title": "A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menopause"
      ],
      "interventions": [
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Progesterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TherapeuticsMD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 1845,
      "start_date": "2013-08-05",
      "completion_date": "2016-10-28",
      "has_results": true,
      "last_update_posted_date": "2019-05-06",
      "last_synced_at": "2026-11-01T01:35:12.172Z",
      "location_count": 119,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942668"
    }
  ]
}